Cetuximab may be beneficial beyond progression in certain patients with mCRC
the ONA take:
According to new findings presented at the ESMO 17th World Congress on Gastrointestinal Cancer in Barcelona, Spain, researchers have found that continuing second-line cetuximab beyond progression following first-line chemotherapy and an anti-epidermal growth factor receptor (EGFR) monoclonal antibody is beneficial for patients with metastatic colorectal cancer who do not have KRAS, NRAS, BRAF, or PIK3CA gene mutations.
For the phase II study, researchers enrolled 340 patients with metastatic colorectal cancer and KRAS exon 2 wild-type tumors. All participants received first-line treatment with FOLFIRI plus cetuximab until unacceptable toxicity or disease progression. Those who experienced disease progression were then randomly assigned 1:1 to receive second-line FOLFOX plus cetuximab or FOLFOX alone.
Results showed that patients with quadruple wild-type metastatic colorectal cancer had significantly improved progression-free survival, improved overall survival, and improved response rates with the addition of second-line cetuximab. These patients were most likely to have an EGFR-dependent tumor.
The authors note that further studies are warranted to confirm these findings in a larger patient population.
Continuing second-line cetuximab beyond progression following first-line chemo and an anti-EGFR monoclonal antibody is beneficial for quadruple wild-type metastatic
- Sexual Dysfunction in Women With Cancer: A Review of Available Interventions
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Worse Survival Seen for Alternative Versus Usual Cancer Therapy
- Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin
- Early Recognition of Checkpoint Inhibitor-Related Pneumonitis Improves Outcomes
- Lenalidomide After ASCT Prolongs Time to Progression in Multiple Myeloma
- Arthritis Medication Shows Potential in the Treatment of Polycythemia Vera
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|